COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination.

Immunocompromised patients, including solid organ transplant recipients (SOTRs), were not included in the two large trials of Pfizer/BioNTech and Moderna mRNA vaccines, and therefore, safety and efficacy data are lacking in this population. Recently, immunogenicity, at a median of 29 days, after dose 2 of the mRNA SARS-CoV-2 vaccines have been studied among 658 SOTRs. 46% of participants did not mount anti spike antibody responses suggesting that such patients may remain at high risk for COVID-19 despite vaccination.